Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and cardiovascular agents

rosiglitazone has been researched along with cardiovascular agents in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S1
Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T1
Bloomgarden, ZT1
Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B1
Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R; Zhi, H1
Koch, A1
Duan, Y; Fu, X; Gao, H; Liu, Y; Xie, C; Xie, H; Yuan, H; Zhou, M1

Trials

1 trial(s) available for rosiglitazone and cardiovascular agents

ArticleYear
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
    American heart journal, 2004, Volume: 147, Issue:5

    Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones

2004

Other Studies

6 other study(ies) available for rosiglitazone and cardiovascular agents

ArticleYear
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
    DNA and cell biology, 2004, Volume: 23, Issue:5

    Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors

2004
The Avandia debate.
    Diabetes care, 2007, Volume: 30, Issue:9

    Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones

2007
Antiatherosclerotic effect of farnesoid X receptor.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:2

    Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha

2009
Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro.
    Cardiovascular diabetology, 2011, Jan-26, Volume: 10

    Topics: Angiotensin II; Animals; Aortic Diseases; Atherosclerosis; Blotting, Western; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Hypercholesterolemia; Immunohistochemistry; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Radioimmunoassay; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors

2011
[Benefits and harms - two sides of the same medal?].
    Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 2011, Volume: 105, Issue:3

    Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Germany; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones

2011
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Animals; Aorta, Abdominal; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression; Humans; Hypoglycemic Agents; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phytotherapy; Rosiglitazone; Signal Transduction

2018